Dissecting pathways of cancer-associated cachexia and its evidence-based relation to vitamin D
Abstract
Introduction: Cancer-associated cachexia (CAC) is a complex metabolic syndrome. It affects 0,5-1% of the general population and 60-83% of cancer patients. Vitamin D has a potential immunological role in cancer cachexia. However, the mechanism remains unclear. Method: This review outlines the complex mechanisms of CAC, a metabolic syndrome marked by muscle loss affecting 80% of cancer patients and the potential action of vitamin D. We highlight the limited studies exploring vitamin D’s impact on CAC, based on cachexia parameters. Result: The Warburg effects in CAC are understood to involve elevated energy use, driven by the tumor microenvironment (TME) and pro-inflammatory cytokines. This present review explores the mechanism of cachexia on skeletal, adipose tissue, liver and tumor microenvironment. At the same time vitamin D deficiency in cancer correlates with poor prognosis due to its critical role in immune modulation. Notably, various clinical trials showed the beneficial roles of vitamin D in reducing inflammation, pain and increasing weight. Conclusion: Few studies had explored the beneficial effects of vitamin D in cancer; However, limited evidence exists on immunomodulatory effects of vitamin D. This critical gaps stressing the need for further clinical research across various cancer types.Downloads
References
Dunne RF, Mustian KM, Garcia JM, Dale W, Hayward R, Roussel B, et al. Research priorities in cancer cachexia: The University of Rochester Cancer Center NCI Community Oncology Research Program Research Base Symposium on Cancer Cachexia and Sarcopenia. Curr Opin Support Palliat Care. 2017;11(4):278-86. https://doi.org/10.1097/SPC.0000000000000301.
Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489-95. https://doi.org/10.1016/s1470-2045(10)71218-7.
von Haehling S, Anker MS, Anker SD. Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016. J Cachexia Sarcopenia Muscle. 2016;7:507-9. https://doi.org/10.1002/jcsm.12167.
Argilés JM, López-Soriano FJ, Toledo M, Betancourt A, Serpe R, Busquets S. The cachexia score (CASCO): a new tool for staging cachectic cancer patients. J Cachexia Saropenia Muscle. 2011;2:87-93. https://doi.org/10.1007/s13539-011-0027-5.
Argilés JM, Betancourt A, Guàrdia-Olmos J, Peró-Cebollero M, López-Soriano FJ, Madeddu C, et al. Validation of the cachexia score (CASCO). staging cancer patients: the use of minicasco as a simplified tool. Front Physiol. 2017;8:92. https://doi.org/10.3389/fphys.2017.00092.
Gingrich A, Volkert D, Kiesswetter E, Thomanek M, Bach S, Sieber CC, et al. Prevalence and overlap of sarcopenia, frailty, cachexia and malnutrition in older medical inpatients. BMC Geriatr. 2019; 19:120-9. https://doi.org/10.1186/s12877-019-1115-1.
Lim S, Brown JL, Washington TA, Greene NP. Development and progression of cancer cachexia: perspectives from bench to bedside. Sports Med Health Sci. 2020;2(4): 177-85. https://doi.org/10.1016/j.smhs.2020.10.003.
Gupta D, Vashi PG, Trukova K, Lis CG, Lammersfeld CA. Prevalence of serum vitamin D deficiency and insufficiency in cancer: Review of the epidemiological literature. Exp Ther Med. 2011;2(2):181-93. https://doi.org/10.3892/etm.2011.205.
Clemente-Suárez VJ, Redondo-Flórez L, Rubio-Zarapuz A, Martínez-Guardado I, Navarro-Jiménez E, Tornero-Aguilera JF. Nutritional and Exercise Interventions in Cancer-Related Cachexia: An Extensive Narrative Review. Int J Environ Res Public Health. 2022;19(8):4604. https://doi.org/10.3390/ijerph19084604.
Chandler PD, Chen WY, Ajala ON, Hazra A, Cook N, Bubes V, et al. Effect of vitamin D3 supplements on development of advanced cancer: A secondary analysis of the VITAL randomized clinical trial. JAMA Netw Open. 2020;3(11):e2025850. https://doi.org/10.1001/jamanetworkopen.2020.25850.
Muscaritoli M, Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, et al. ESPEN practical guideline: clinical nutrition in cancer. Clin Nutr. 2021; 40(5): 2898-913. https://doi.org/10.1016/j.clnu.2021.02.005.
Sassi F, Tamone C, D’Amelio P. Vitamin D: nutrient, hormone, and immunomodulator. Nutrients. 2018; 10(11): 1656. https://doi.org/10.3390/nu10111656.
Archid R, Solass W, Tempfer C, Königsrainer A, Adolph M, Reymond MA, et al. Cachexia Anorexia Syndrome and Associated Metabolic Dysfunction in Peritoneal Metastasis. Int J Mol Sci. 2019;20(21):5444. https://doi.org/10.3390/ijms20215444.
Peixoto da Silva S, Santos JMO, Costa E Silva MP, Gil da Costa RM, Medeiros R. Cancer cachexia and its pathophysiology: links with sarcopenia, anorexia and asthenia. J Cachexia Sarcopenia Muscle. 2020;11(3):619-35. https://doi.org/10.1002/jcsm.12528.
Benny S, Mishra R., Manojkumar MK, Aneesh TP. From Warburg effect to Reverse Warburg effect; The new horizons of Anti-Cancer therapy. Med Hypotheses. 2020; 144:110216. https://doi.org/10.1016/j.mehy.2020.110216.
Xu XD, Shao SX, Jiang HP, Cao, YW, Wang YH, Yang XC et al. Warburg effect or reverse Warburg effect? A review of cancer metabolism. Oncol Res Treat. 2015;38(3):117-22. https://doi.org/10.1159/000375435.
Visavadiya NP, Rossiter HB, Khamoui AV. Distinct glycolytic pathway regulation in liver, tumour and skeletal muscle of mice with cancer cachexia. Cell Biochem Funct. 2021;39(6):802-12. https://doi.org/10.1002/cbf.3652.
Wang YF, An ZY, Lin DH, Jin WL. Targeting cancer cachexia: Molecular mechanisms and clinical study. MedComm.2022;3(4):e164. https://doi.org//10.1002/mco2.164.
Bonaficio A, Sanvee GM, Brecht K, Kratschmar DV, Odermatt A, Bouitbir J, et al. IGF-1 prevent simvastatin-induced myotoxicity in C2C12 myotubes. Arch Toxicol 2016. doi:10.1007/s00204-016-1871-z
Petruzzelli M, Wagner EF. Mechanisms of metabolic dysfunction in cancer-associated cachexia. Genes Dev. 2016;30(5):489-501. https://doi.org/10.1101/gad.276733.115.
Olson B, Diba P, Korzun T, Marks DL. Neural Mechanisms of Cancer Cachexia. Cancers (Basel). 2021;13(16):3990. https://doi.org/10.3390/cancers13163990.
Borner T, Liberini CG, Lutz TA, Riediger T. Brainstem GLP-1 signalling contributes to cancer anorexia-cachexia syndrome in the rat. Neuropharmacology. 2018;131:282-290. https://doi.org/10.1016/j.neuropharm.2017
Rounis K, Makrakis D, Gioulbasanis I, Ekman S, De Petris L, Mavroudis D et al. Cancer Cachexia and Antitumor Immunity: Common Mediators and Potential Targets for New Therapies. Life (Basel). 2022;12(6):880. https://doi.org/10.3390/life12060880.
Miller J, Laird BJA, Skipworth RJE. The immunological regulation of cancer cachexia and its therapeutic implications. J Cancer Metastasis Treat. 2019;5:68. http://dx.doi.org/10.20517/2394-4722.2019.001.
Grossberg AJ, Vichaya EG, Christian DL, Molkentine JM, Vermeer DW, Gross PS et al. Tumor-Associated Fatigue in Cancer Patients Develops Independently of IL1 Signaling. Cancer Res. 2018;78(3):695-705. https://doi.org/10.1158/0008-5472.CAN-17-2168.
Wyart E, Bindels LB, Mina E, Menga A, Stanga S, Porporato PE, Cachexia, a systemic disease beyond muscle atrophy. Int J Mol Sci. 2020, 21(22):8592. https://doi.org/10.3390/ijms21228592.
Liu W, Zhang L, Xu HJ, Li Y, Hu CM, Yang JY, et al. The anti-inflammatory effects of vitamin D in tumorigenesis. Int J Mol Sci. 2018; 19: 2736. https://doi.org/10.3390/ijms19092736.
Baazim H, Antonio-Herrera L, Bergthaler A. The interplay of immunology and cachexia in infection and cancer. Nat Rev Immunol. 2022;22(5):309-321. https://doi.org/10.1038/s41577-021-00624-w.
Karagul MI, Aktas S, Yetkin D, Bayrak G, Celikcan D. P53, Bcl2, and Bax Expression and Apoptosis in Perifosine and Vitamin D-Treated Endometrial Cancer Cell Line (HEC1A). Proceedings. 2018; 2:4. https://doi.org/10.3390/proceedings2251564
Kizildag S, Ates H, Kizildag S. Treatment of K562 cells with 1,25-dihydroxyvitamin D3 induces distinct alterations in the expression of apoptosis-related genes BCL2, BAX, BCLXL, and p21. Ann Hematol. 2010; 89: 5. https://doi.org/10.1007/s00277-009-0766-y.
Lee WL, Wang PH. Immunology and ovarian cancers. J Chin Med Assoc. 2020;83(5):425-432. https://doi.org/10.1097/JCMA.0000000000000283.
Dancsok AR, Gao D, Lee AF, Steigen SE, Blay JY, Thomas DM et al. Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas. Oncoimmunology. 2020 Apr 12;9(1):1747340. https://doi.org/10.1080/2162402X.2020.1747340.
Costamagna D, Duelen R, Penna F, Neumann D, Costelli P, Sampaolesi M. Interleukin-4 administration improves muscle function, adult myogenesis, and lifespan of colon carcinoma-bearing mice. J Cachexia Sarcopenia Muscle. 2020;11(3):783-801. https://doi.org/10.1002/jcsm.12539.
Barker T, Fulde G, Moulton B, Nadauld LD, Rhodes T. An elevated neutrophil-to-lymphocyte ratio associates with weight loss and cachexia in cancer. Sci Rep. 2020;10:7535. https://doi.org/10.1038/s41598-020-64282-z.
Derman BA, Macklis JN, Azeem MS, Sayidine S, Basu S, Batus M et al. Relationships between longitudinal neutrophil to lymphocyte ratios, body weight changes, and overall survival in patients with non-small cell lung cancer. BMC Cancer. 2017;17:141. https://doi.org/10.1186/s12885-017-3122-y.
Petruzzelli M, Ferrer M, Schuijs MJ, Kleeman SO, Mourikis N, Hall Z et al. Early Neutrophilia Marked by Aerobic Glycolysis Sustains Host Metabolism and Delays Cancer Cachexia. Cancers (Basel). 2022;14(4):963. https://doi.org/10.3390/cancers14040963.
Pinto MP, Balmaceda C, Bravo ML, Kato S, Villarroel A, Owen GI et al. Patient inflammatory status and CD4+/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer. Gynecol Oncol. 2018;151(1):10-17. https://doi.org/10.1016/j.ygyno.2018.07.025.
Baazim H, Schweiger M, Moschinger M, Xu H, Scherer T, Popa A et al. CD8+ T cells induce cachexia during chronic viral infection. Nat Immunol. 2019;20(6):701-710. https://doi.org/10.1038/s41590-019-0397-y.
Wang Z, Zhao C, Moya R, Davies JD. A novel role for CD4+ T cells in the control of cachexia. J Immunol. 2008;181(7):4676-84. https://doi.org/10.4049/jimmunol.181.7.4676.
Laird E, Ward M, Mc Sorley E, Strain JJ, Wallace J. Vitamin D and bone health. Potential mechanism. Nutrients 2010, 2, 693-724; doi:10.3390/nu2070693
El-Sharkawy A, Malki A. Vitamin D Signaling in Inflammation and Cancer: Molecular Mechanisms and Therapeutic Implications. Molecules. 2020;25(14):3219. https://doi.org/10.3390/molecules25143219.
Dovnik A, Dovnik NF. Vitamin D and ovarian cancer: systematic review of the literature with a focus on molecular mechanisms. Cells. 2020; 9(2): 335. https://doi.org/10.3390/cells9020335.
Sustova H, De Faudis M, Reano S, Teixeira MA, Valle I, Zaggia I, Agosti E, et al. Opposing effect of 25‐hydroxy‐ and 1α,25‐dihydroxy‐vitamin D3 on pro‐cachectic cytokine‐and cancer conditioned medium‐ induced atrophy in C2C12 myotubes. Acta Physiologica. 2019;226:e13269.https://doi.org/10.1111/apha.13269.
Camperi A, Pin F, Costamagna D, Penna F, Menduina ML, Aversa Z, et al. Vitamin D and VDR in cancer cachexia and muscle regeneration. Oncotarget 2017;8(13):21778-21793. doi: 10.18632/oncotarget.15583.
Van Veldhuizen PJ, Taylor SA, Williamson S, Drees BM. Treatment of vitamin D deficiency in patients with metastatic prostate cancer may improve bone pain and muscle strength. J Urol. 2000; 163(1):187–190. https://doi.org/ 10.1097/00005392-200001000-00044.
Hoffer LJ, Robitaille L, Swinton N, Agulnik J, Cohen V, Small D et al. Appropriate vitamin D loading regimen for patients with advanced lung cancer. Nutr J. 2016;15(1):84. https://doi.org/10.1186/s12937-016-0203-8.
Haidari F, Abiri B, Iravani M, Ahmadi-Angali K, Vafa M. Randomized Study of the Effect of Vitamin D and Omega-3 Fatty Acids Cosupplementation as Adjuvant Chemotherapy on Inflammation and Nutritional Status in Colorectal Cancer Patients. J Diet Suppl. 2020;17(4):384-400. https://doi.org/10.1080/19390211.2019.1600096.
Peppone LJ, Ling M, Huston AJ, Reid ME, Janelsins MC, Puzas JE, et al. The effects of high-dose calcitriol and individualized exercise on bone metabolism in breast cancer survivors on hormonal therapy: a phase II feasibility trial. Support Care Cancer. 2018;26(8):2675-2683. https://doi.org/10.1007/s00520-018-4094-4.
Brenner H, Kuznia S, Laetsch C, Niedermaier T, Schöttker B. Prevention of Advanced Cancer by Vitamin D3 Supplementation: Interaction by Body Mass Index Revisited. Nutrients. 2021;13(5):1408. https://doi.org/10.3390/nu13051408.
Analan PD, Kaya E. The Effect of Serum 25(OH)D3 Level on Breast Cancer-Related Lymphedema. Lymphat Res Biol. 2020:18(1):22-26. https://doi.org/10.1089/lrb.2018.0071.
Dev R, Del Fabbro E, Schwartz GG, Hui D, Palla SL, Gutierrez N, et al. Preliminary report: vitamin D deficiency in advanced cancer patients with symptoms of fatigue or anorexia. Oncologist. 2011; 16:1637–1641. http://dx.doi.org/10.1634/theoncologist.2011-0151
Klement RJ, Koebrunner PS, Krage K, Sweeney RA. Low Vitamin D Status in a Cancer Patient Population from Franconia, Germany. Complement Med Res. 2021;28(4):300-307. https://doi.org/10.1159/000511993.
Castellano-Castillo D, Morcillo S, Clemente-Postigo M, Crujeiras AB, Fernandez-García JC, Torres E et al. Adipose tissue inflammation and VDR expression and methylation in colorectal cancer. Clin Epigenetics. 2018;10:60. https://doi.org/10.1186/s13148-018-0493-0.
Xie DD, Chen YH, Xu S, Zhang C, Wang DM, Wang H et al. Low vitamin D status is associated with inflammation in patients with prostate cancer. Oncotarget. 2017;8(13):22076-22085. https://doi.org/10.18632/oncotarget.16195.
Skender S, Böhm J, Schrotz-King P, Chang-Claude J, Siegel EM, Steindorf K et al. Plasma 25-Hydroxyvitamin D3 Levels in Colorectal Cancer Patients and Associations with Physical Activity. Nutr Cancer. 2017;69(2):229-237. https://doi.org/10.1080/01635581.2017.1265131.
Submitted
Copyright (c) 2026 Nurul Ratna Manikam, Andrijono, Fariz Nurwidya, Fiastuti Witjaksono, Isabela Andhika Paramita
This work is licensed under a Creative Commons Attribution 4.0 International License.
World Nutrition Journal provides immediate open access to its content under the Creative Commons Attribution License (CC BY 4.0). This permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
